Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Roudy who wrote (1645)	3/15/1999 12:44:00 PM
From: scaram(o)uche	Respond to of 1762

>> This drug sounds remarkably similar to THP-dox, a tumor homing peptide laced with doxorubicin that is presently being developed by ILXO and the Burnham Institute. << An very valuable observation to me. Can't thank you enough. Rick

To: Roudy who wrote (1645)	3/22/1999 3:21:00 PM
From: Roudy	Read Replies (1) \| Respond to of 1762

(posting from Yahoo)salomon...reiterates...target $60 by: RU2L8 671 of 671"we expect idec to exceed their previous guidance of $48-$51mm in rituxan sales for 1q99. .......thus we believe hat $250mm rituxan sales for 99 are highly conservative....we would use any weakness as a buying opportunity." this analyst has been right on with idph.....sheis looking for eps of 1.05 1999//1.50 2000//2.50 in 2001...... hope this gives the board some updates.